FOSUN PHARMA Secures Regulatory Approval for Bond Offering to Professional Investors
Stock News
Feb 26
FOSUN PHARMA (02196) has announced that the company recently received approval from the China Securities Regulatory Commission (CSRC) for its application to issue science and technology innovation corporate bonds to professional investors. According to the approval notice, the CSRC has consented to the company's plan to publicly issue these bonds with a total face value not exceeding RMB 6 billion. The approval is valid for 24 months from the date of issuance. During this period, FOSUN PHARMA may issue the science and technology innovation corporate bonds in multiple tranches.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.